With just a few days until the Commission publishes both its Industrial Strategy and the roadmap for the upcoming Pharmaceutical Strategy, the future of Europe’s life sciences sector is in sharp focus.  

The publication of both documents is eagerly anticipated. Much rests on their content; for patients across Europe, for the European economy and Europe’s life science community. 

In the midst of a coronavirus epidemic, attention turns to the research-based industry to rapidly develop diagnostics, vaccines and treatments in response to such a significant public health threat. It underlines the need for an infrastructure and policy environment that supports medical research in Europe.